Moeller, Joerg
This speaker appears at this event:

This speaker’s events are being finalized

Joerg Moeller, MD, PhD

    • Head of Research & Development, Pharmaceuticals Division, Bayer AG

Joerg Moeller, MD is the global Head of Research and Development (R&D) at Bayer AG’s Pharmaceuticals Division and a member of the Executive Committee of the Division. He is also serving as a member of the Board of Directors of BlueRock Therapeutics, Cambridge (MA, USA).
Under his leadership, the R&D function has developed and is implementing a new global innovation model that puts a strong emphasis on productive, innovative collaborations models with leading academic institutions, small and large biotech players and established pharmaceutical companies. The focus is on addressing high medical need disease conditions predominantly in oncology, cardiovascular and gynecological diseases.
Prior to his current role, Joerg Moeller was the global Head of Pharmaceuticals Development since 2014 and led the Clinical Development function between 2003 and 2014. During this time and during his tenure and responsibility for clinical development, he was instrumental in developing to global approval innovative agents like Rivaroxaban (Xarelto®), Aflibercept (Eylea®), Sorafenib (Nexavar®), Regorafenib (Stivarga®), Alpharadin (Xofigo®), Damoctocoq alpha pegol (Jivi®), Octocoq alpha (Kovaltry®), Moxifloxacin (Avelox®), Vardenafil (Levitra®).
Joerg Moeller joined Bayer AG in 1993 from academic medicine in Orthopedic Surgery at Ruhr-University Bochum, Germany. Initially being responsible for global late stage development of a cardio-vascular compound, he became responsible for cardiovascular new business development in 1996. From 1998 until the end of 2001, Dr. Moeller held positions of increasing responsibility in clinical development at Bayer Corporation, West Haven, CT (USA) and at Bayer Inc., HealthCare Division, Toronto (Canada).

Gene and Cell Therapy

May 10–12, 2021